Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.
Botanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section, in an article about the shipment of the Company’s ‘first batch of sweat-stopper gel’ to US patients by Cheyanne Enciso.
https://botanixpharma.com/wp-content/uploads/Copy-of-BOT-website-announcement-1-1.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-12-29 19:06:382024-12-29 19:06:39The West Australian: ‘Botanix ships first batch of sweat-stopper gel’
First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.
Botanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.
https://botanixpharma.com/wp-content/uploads/BOT_Website.png7361104Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-11-19 02:40:082024-11-19 02:40:08Botanix presentation at Bell Potter Healthcare Conference
Ascent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (or nearly 40%) of US commercial lives.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held A$68.67 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product.
Botanix Releases Quarterly Reports
/in ASX Releases, Featured, Latest News, News /by Haley ChartresQuarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.
The West Australian: ‘Botanix ships first batch of sweat-stopper gel’
/in Featured, Latest News, News /by Haley ChartresBotanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section, in an article about the shipment of the Company’s ‘first batch of sweat-stopper gel’ to US patients by Cheyanne Enciso.
Read article
First Sofdra™ prescriptions as commercialization ramps up
/in ASX Releases, Featured, Latest News, News /by Haley ChartresFirst prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.
View release.
Botanix presentation at Bell Potter Healthcare Conference
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.
View ASX release.
Botanix adds Payer coverage representing ~65 million commercial lives
/in ASX Releases, Featured, Latest News, News /by Haley ChartresAscent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (or nearly 40%) of US commercial lives.
View release.
Botanix Releases Quarterly Reports
/in ASX Releases, Featured, Latest News, News /by Haley ChartresQuarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held A$68.67 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product.
View Report.